Condensed Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows From Operating Activities
Net loss	$ (1,067,984)	$ (662,963)
Adjustments to reconcile net loss to net cash used by operating activities:
Stock options issued for research and development expense	223,985	159,839
Stock options granted for officer compensation	435,570	213,530
Warrants granted as financing costs	0	3,400
Non cash interest expense	94,332	0
Accretion of debt discount	98,049	35,380
Change in derivative liabilities	57,140	57,203
Changes in operating assets and liabilities:
Decrease prepaid expenses	0	56,265
(Decrease) increase accounts payable and accrued liabilities	41,917	(91,908)
(Decrease) increase accounts payable and accrued liabilities - related party	(5,576)	8,861
Net cash (used by) operating activities	(122,567)	(220,393)
Cash Flows From Investing Activities
Net cash provided from used by investing activities	0	0
Cash Flows From Financing Activities
Proceeds from private placement	0	100,000
Proceeds from convertible notes	100,000	10,000
Proceeds from related party advances	0	101,000
Net cash provided from financing activities	100,000	211,000
Decrease in cash and cash equivalents	(22,567)	(9,393)
Cash at beginning of year	57,632	67,025
Cash at end of period	35,065	57,632
SUPPLEMENTAL DISCLOSURES
Interest paid	0	0
Income taxes paid	0	0
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Derivative liability associated with debt discount	51,009	0
Derivative liability associated with warrants	$ 143,323	$ 0